Investors Shouldn't Be Too Comfortable With Haisco Pharmaceutical Group's (SZSE:002653) Earnings
Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) just reported some strong earnings, and the market reacted accordingly with a healthy uplift in the share price. We did some analysis and think tha
The Recent CN¥894m Market Cap Decrease Is Likely to Have Disappointed Insiders Invested in Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)
Key Insights Significant insider control over Haisco Pharmaceutical Group implies vested interests in company growth 60% of the business is held by the top 2 shareholders Ownership research, combi
HiCisco (002653.SZ): Net profit of 91.9559 million yuan in the first quarter increased 219.86% year over year
On April 19, GLONGHUI (002653.SZ) released its first quarter report. Operating revenue was 752 million yuan, up 20.60% year on year, net profit of 91.9559 million yuan, up 219.86% year on year, after deducting non-net profit of 29.74 million yuan, up 4.37% year on year, with basic earnings of 0.08 yuan per share.
Haisco Pharmaceutical Gets Nod to Trial HSK16149 Capsules
Haisco Pharmaceutical Group (SHE:002653) will hold clinical trials on the HSK16149 capsules after getting the approval of China's National Medical Products Administration, according to the company's d
HiCisco (002653.SZ): HSK16149 capsule clinical trial approved
HiCisco (002653.SZ) issued an announcement. The company recently received “Drugs...” issued by the State Drug Administration
Haisco Pharma Gets Nod to Trial Asthma Drug
China's National Medical Products Administration approved Haisco Pharmaceutical Group's (SHE:002653) application to conduct clinical trials on the HSK31858 tablet, the company said in its filing on th
Haisco Pharma Gets Nod to Trial HSK16149 Capsule as Central Neuropathic Pain Drug
Haisco Pharmaceutical Group (SHE:002653) will hold a clinical trial on the HSK16149 capsule after receiving approval from China's National Medical Products Administration, according to the company's d
HiCisco (002653.SZ): Received 69.3619 million yuan in industrial development support funds
Gelonghui, March 31, 丨 HiCisco (002653.SZ) announced that the company and its subsidiary Tibet Haize Marketing Management Co., Ltd. (“Tibet Haize”) received a total of 69.3619 million yuan in industrial development support funds disbursed by the Tibet Shannan Happy Home Construction Administration on March 29, 2024. The above funds have already been paid. The industrial development support funds received this time are related to the company's daily business activities and are not sustainable.
These 4 Measures Indicate That Haisco Pharmaceutical Group (SZSE:002653) Is Using Debt Reasonably Well
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' When we think about how risky a company is, we always like
What Haisco Pharmaceutical Group Co., Ltd.'s (SZSE:002653) 26% Share Price Gain Is Not Telling You
Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) shareholders would be excited to see that the share price has had a great month, posting a 26% gain and recovering from prior weakness. Longer-te
HiCisco (002653.SZ): Proposed capital increase for subsidiary HiCisco of the United States
HiCisco (002653.SZ) announced that its subsidiary, Sichuan Hisco Pharmaceutical Co., Ltd. (“Sichuan HiCisco”), used its own capital to fund its subsidiary HAISCO HOLDINGS PTE.LTD. (hereinafter referred to as “Hisco Holdings”) increased its capital by US$40 million.
HiCisco (002653.SZ): Innovative drug HSK39775 tablets approved for clinical trials
HiCisco (002653.SZ) announced that Tibet Hisco Pharmaceutical Co., Ltd., a subsidiary of the company (hereinafter referred to as the “Company”), recently received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration. HSK39775 tablets, intended for the treatment of advanced solid tumors.
Has Haisco Pharmaceutical Group Co., Ltd.'s (SZSE:002653) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Haisco Pharmaceutical Group (SZSE:002653) has had a great run on the share market with its stock up by a significant 5.7% over the last month. We wonder if and what role the company's financials pla
HiCisco (002653.SZ) plans to establish a wholly-owned subsidiary in Australia to promote clinical research of products overseas
Zhitong Financial App News, HiCisco (002653.SZ) announced that the 10th meeting of the 5th board of directors of the company reviewed and passed the “Proposal on the Company's Establishment of a Wholly-owned Subsidiary in Australia”, agreeing that the company's wholly-owned subsidiary Haisco Holdings Group Limited (“Hisco Holding Group”) plans to establish its wholly-owned subsidiary HAISCO INNOVATIVE PHARMACEUTICAL (AUSCO) PTY in Australia with its own capital of 50,000 Australian dollars LTD. (Proposed name).
HiCisco (002653.SZ): In the short term, the underlying technology such as blockchain will not be directly invested in business operations
HiCisco (002653.SZ) stated on the interactive platform that blockchain technology, as an advanced technology, will not directly affect the maintenance of customer relationships and the company's competitive advantage in the market.
[BT Financial Report Momentary Analysis] HiCisco 2023 Quarterly Report: Steady growth in performance, significant improvement in financial situation
As a diversified listed company in the pharmaceutical field, HiCisco (stock code: 002653) is a diversified listed company in the pharmaceutical field. Its main business covers pharmaceutical R&D, manufacturing and sales.
Haisco Pharmaceutical Group's (SZSE:002653) Investors Will Be Pleased With Their Strong 138% Return Over the Last Five Years
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on a lighter note, a good company can see its share price rise well over 100%. For instance, the price
HiCisco (002653.SZ): Plans to set up a subsidiary of Haiyue Tibet Marketing Management for 10 million yuan
HiCisco (002653.SZ) announced that the 9th meeting of the 5th board of directors of the company reviewed and passed the “Proposal on the Company's Establishment of a Subsidiary in Shannan City, Tibet Autonomous Region” and agreed that the company would establish a subsidiary, Tibet Haiyue Marketing Management Co., Ltd. (proposed name).
HiCisco (002653.SZ): Received a notice of acceptance of the IND application for the new indication of the innovative drug HSK39297 tablets
On January 11, Gelonghui (002653.SZ) announced that the company's subsidiary Tibet Hisco Pharmaceutical Co., Ltd. recently received a “Notice of Acceptance” for HSK39297 tablets issued by the State Drug Administration. HSK39297 is a new drug independently developed by the company to treat hemolytic diseases with independent intellectual property rights. According to the requirements for chemical drug registration classification in the notice issued by the State Drug Administration on the “Registration Classification of Chemical Drugs and Application Data Requirements” (No. 44 of 2020), this product is a chemical drug category 1. Pre-clinical research results show that the target of this product is clear
HiCisco (002653.SZ): Received a notice of acceptance of the IND application for the innovative drug HSK16149 capsules for new indications
Gelonghui, January 10 | HiCisco (002653.SZ) announced that the company recently received the “Notice of Acceptance” issued by the State Drug Administration, which is an HSK16149 capsule.
No Data